Quintiles (#Quintiles), the leading global Contract Research Organization (CRO), continues to share with the biopharmaceutical industry (and on a more macro level – the global healthcare industry) its latest insights and developments about the dynamic healthcare industry. It reflects on the fast moving and ever evolving healthctare (#healthcare) industry that they find themselves in to be a rapidly-changing industry where the perceptions of stakeholders, their demands and needs continue to morph over time.
In its latest November 2011 release, The New Health report commissioned by Quintiles, explores consumer and industry sentiments in the drug development universe of today. The web of interconnectivity of needs, relations and responsibilities between healthcare stakeholders create an incredible influence on drug development cycles and collectively affect the future and direction of the healthcare industry.
Quintiles recognizes that each stakeholder group has a different evidence requirement in determining the "value" of healthcare, and highlights in its report that appraising these needs and designing trials to address them will go a long way towards appropriately aligning development portfolios with marketplace realities. Engaging the entire constellation of stakeholders toward a common purpose, and incorporating the needs of the value chain into clinical development, will better help drug developers and their partners develop the right products to market.
Ongoing collaboration and increased communication between the community of stakeholders, beginning from the drug developers to the patients and their physicians, as well as payers and policymakers are pertinent to align the perception gaps between each group.Â Nonetheless, survey results have shown that there seems to be a sustained level of optimism across various stakeholder groups for both the future of healthcare and prescription medications, despite divergent perceptions of "value" and widely disparate views of evidence requirement.
Key topics discussed in "The New Health" report include, "Value in Healthcare", "Stakeholder roles and performance" and the "Future of Healthcare and Medicine". It states "Among all stakeholder groups, ongoing collaboration and increased communication are paramount to aligning the perception gaps that stymie innovation and thwart innovation."
Quintiles is proud to be the Exclusive "Diamond Sponsor" at the 5th annual BioPharma Asia Convention 2012. If you would like to meet with their consultants and BD team to explore partnership opportunities, contact Rebecca Koh at firstname.lastname@example.org now to arrange a meeting today!
More about Quintiles
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide.
Our Asia Pacific presence began in 1982; there are now more than 20 offices in 14 countries in the region, so we can find a multitude of ways to help you turn healthy ideas into healthy people. Working to find flexible ways to help you accelerate outcomes, offering both insight and action from strategic business consulting to operational delivery using our in region resources ranging from data management and cardiac safety to Central Labs in China, India and Singapore.
Voted 2010 Asia Pacific CRO of the Year by Frost & Sullivan we have built our reputation in the region on the quality and results we have delivered across 1,700 studies involving 230+ partner and 4,000+ non partner sites. Quintiles' combination of global, regional and local expertise across a range of therapeutic areas including oncology, vaccines, neurology and cardiovascular disease has never been more important. For more information, please visit www.quintiles.com.